<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00694148</url>
  </required_header>
  <id_info>
    <org_study_id>MRZ 60201 GL_3001</org_study_id>
    <secondary_id>2008-000549-73</secondary_id>
    <nct_id>NCT00694148</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of NT 201, Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines</brief_title>
  <official_title>NT 201 is a Botulinum Toxin Type A Preparation Free of Complexing Proteins. Injected Into the Muscle, NT 201 Causes a Reversible Local Relaxation of the Injected Muscle. Botulinum Toxin Type A is Widely Used for Aesthetic Treatment of Mimic Wrinkles. This Study Will Investigate the Safety and Efficacy of NT 201 in the Treatment of Glabellar Frown Lines.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merz Pharmaceuticals GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz Pharmaceuticals GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      NT 201 is a Botulinum toxin type A preparation free of complexing proteins. Injected into the
      muscle, NT 201 causes a reversible local relaxation of the injected muscle. Botulinum toxin
      type A is widely used for aesthetic treatment of mimic wrinkles. This study will investigate
      the safety and efficacy of NT 201 in the treatment of glabellar frown lines.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator`s assessment</measure>
    <time_frame>4 weeks after initial injection session</time_frame>
  </primary_outcome>
  <enrollment type="Actual">108</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NT 201</intervention_name>
    <description>A Botulinum neurotoxin type A, free of complexing proteins
Detailed described in study protocol</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  moderate to severe glabellar frown lines at maximum frown ((severity score of 2 or 3
             on Facial Wrinkle Scale(FWS)as assessed by the investigator's rating: 0 = 'none', 1 =
             'mild', 2 = 'moderate', 3 = 'severe'

          -  Stable medical condition

          -  Age: between 18 and 65 years (inclusively)

        Exclusion Criteria:

          -  Previous treatment with Botulinum toxin of any serotype in the upper third part of the
             face within the last 6 month

          -  Previous treatment with biodegradable fillers in the glabellar area within the last 12
             month

          -  Previous insertion of permanent material in the glabellar area, including fat graft
             (regardless of the time between previous treatment and this study)

          -  Any surgery in the glabellar area including surgical removal of the corrugator,
             procerus, or depressor supercilii muscles or a combination of these, or scars in the
             glabellar area

          -  Any other planned cosmetic procedure in the upper third part of the face during the
             trial period

          -  Inability to substantially lessen glabellar frown lines even by physically spreading
             them apart

          -  Marked facial asymmetry or ptosis of eyelid and/or eyebrow

          -  History of facial nerve palsy

          -  Any infection in the area of the injection sites
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Imhof, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ästhetische Dermatologie, Medico Palais Bad Soden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. Matthias Imhof, Medico Palais Bad Soden</name>
      <address>
        <city>Bad Soden</city>
        <state>Hessen</state>
        <zip>65812</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Imhof M, Kühne U. A Phase III Study of IncobotulinumtoxinA in the Treatment of Glabellar Frown Lines. J Clin Aesthet Dermatol. 2011 Oct;4(10):28-34.</citation>
    <PMID>22010053</PMID>
  </results_reference>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2008</study_first_submitted>
  <study_first_submitted_qc>June 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2008</study_first_posted>
  <last_update_submitted>October 29, 2012</last_update_submitted>
  <last_update_submitted_qc>October 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment of glabellar frown lines</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>incobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

